These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 12084717)

  • 1. Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination.
    Taggart CC; Greene CM; McElvaney NG; O'Neill S
    J Biol Chem; 2002 Sep; 277(37):33648-53. PubMed ID: 12084717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding.
    Taggart CC; Cryan SA; Weldon S; Gibbons A; Greene CM; Kelly E; Low TB; O'neill SJ; McElvaney NG
    J Exp Med; 2005 Dec; 202(12):1659-68. PubMed ID: 16352738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation.
    Lentsch AB; Jordan JA; Czermak BJ; Diehl KM; Younkin EM; Sarma V; Ward PA
    Am J Pathol; 1999 Jan; 154(1):239-47. PubMed ID: 9916938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pervanadate-induced nuclear factor-kappaB activation requires tyrosine phosphorylation and degradation of IkappaBalpha. Comparison with tumor necrosis factor-alpha.
    Mukhopadhyay A; Manna SK; Aggarwal BB
    J Biol Chem; 2000 Mar; 275(12):8549-55. PubMed ID: 10722693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor.
    Mulligan MS; Lentsch AB; Huber-Lang M; Guo RF; Sarma V; Wright CD; Ulich TR; Ward PA
    Am J Pathol; 2000 Mar; 156(3):1033-9. PubMed ID: 10702419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient nuclear factor kappaB (NF-kappaB) activation stimulated by interleukin-1beta may be partly dependent on proteasome activity, but not phosphorylation and ubiquitination of the IkappaBalpha molecule, in C6 glioma cells. Regulation of NF-kappaB linked to chemokine production.
    Uehara T; Matsuno J; Kaneko M; Nishiya T; Fujimuro M; Yokosawa H; Nomura Y
    J Biol Chem; 1999 May; 274(22):15875-82. PubMed ID: 10336492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells.
    Greene CM; McElvaney NG; O'Neill SJ; Taggart CC
    Infect Immun; 2004 Jun; 72(6):3684-7. PubMed ID: 15155685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of secretory leukocyte protease inhibitor on the tumor necrosis factor-alpha production and NF-kappaB activation of lipopolysaccharide-stimulated macrophages.
    Sano C; Shimizu T; Tomioka H
    Cytokine; 2003 Jan; 21(1):38-42. PubMed ID: 12668158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli.
    Henriksen PA; Hitt M; Xing Z; Wang J; Haslett C; Riemersma RA; Webb DJ; Kotelevtsev YV; Sallenave JM
    J Immunol; 2004 Apr; 172(7):4535-44. PubMed ID: 15034071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential IkappaB kinase activation and IkappaBalpha degradation by interleukin-1beta and tumor necrosis factor-alpha in human U937 monocytic cells. Evidence for additional regulatory steps in kappaB-dependent transcription.
    Nasuhara Y; Adcock IM; Catley M; Barnes PJ; Newton R
    J Biol Chem; 1999 Jul; 274(28):19965-72. PubMed ID: 10391945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice.
    Nakamura A; Mori Y; Hagiwara K; Suzuki T; Sakakibara T; Kikuchi T; Igarashi T; Ebina M; Abe T; Miyazaki J; Takai T; Nukiwa T
    J Exp Med; 2003 Mar; 197(5):669-74. PubMed ID: 12615907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipopolysaccharide-induced NF-kappaB activation in human endothelial cells involves degradation of IkappaBalpha but not IkappaBbeta.
    Zen K; Karsan A; Eunson T; Yee E; Harlan JM
    Exp Cell Res; 1998 Sep; 243(2):425-33. PubMed ID: 9743602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo.
    Roff M; Thompson J; Rodriguez MS; Jacque JM; Baleux F; Arenzana-Seisdedos F; Hay RT
    J Biol Chem; 1996 Mar; 271(13):7844-50. PubMed ID: 8631829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-Hydroxynonenal prevents NF-kappaB activation and tumor necrosis factor expression by inhibiting IkappaB phosphorylation and subsequent proteolysis.
    Page S; Fischer C; Baumgartner B; Haas M; Kreusel U; Loidl G; Hayn M; Ziegler-Heitbrock HW; Neumeier D; Brand K
    J Biol Chem; 1999 Apr; 274(17):11611-8. PubMed ID: 10206970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor-alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-kappab activation.
    Han Y; Weinman S; Boldogh I; Walker RK; Brasier AR
    J Biol Chem; 1999 Jan; 274(2):787-94. PubMed ID: 9873017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription.
    McNeely TB; Shugars DC; Rosendahl M; Tucker C; Eisenberg SP; Wahl SM
    Blood; 1997 Aug; 90(3):1141-9. PubMed ID: 9242546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of proteasome inhibitors on monocytic IkappaB-alpha and -beta depletion, NF-kappaB activation, and cytokine production.
    Haas M; Page S; Page M; Neumann FJ; Marx N; Adam M; Ziegler-Heitbrock HW; Neumeier D; Brand K
    J Leukoc Biol; 1998 Mar; 63(3):395-404. PubMed ID: 9500529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor.
    Taggart CC; Lowe GJ; Greene CM; Mulgrew AT; O'Neill SJ; Levine RL; McElvaney NG
    J Biol Chem; 2001 Sep; 276(36):33345-52. PubMed ID: 11435427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced proteolysis of IkappaBalpha and IkappaBbeta proteins in astrocytes by Moloney murine leukemia virus (MoMuLV)-ts1 infection: a potential mechanism of NF-kappaB activation.
    Kim HT; Qiang W; Wong PK; Stoica G
    J Neurovirol; 2001 Oct; 7(5):466-75. PubMed ID: 11582519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway.
    Butler MW; Robertson I; Greene CM; O'Neill SJ; Taggart CC; McElvaney NG
    J Biol Chem; 2006 Nov; 281(46):34730-5. PubMed ID: 16980310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.